Last $13.48 USD
Change Today -0.20 / -1.46%
Volume 3.3M
KERX On Other Exchanges
Symbol
Exchange
KERX is not on other exchanges.
As of 8:10 PM 09/19/14 All times are local (Market data is delayed by at least 15 minutes).

keryx biopharmaceuticals (KERX) Snapshot

Open
$13.75
Previous Close
$13.68
Day High
$13.84
Day Low
$13.40
52 Week High
08/28/14 - $18.48
52 Week Low
10/15/13 - $8.61
Market Cap
1.2B
Average Volume 10 Days
4.9M
EPS TTM
$-0.79
Shares Outstanding
91.8M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for KERYX BIOPHARMACEUTICALS (KERX)

keryx biopharmaceuticals (KERX) Related Bloomberg News

View More Bloomberg News

keryx biopharmaceuticals (KERX) Related Businessweek News

No Related Businessweek News Found

keryx biopharmaceuticals (KERX) Details

Keryx Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of pharmaceutical products for the treatment of renal disease in the United States. It is developing Zerenex (ferric citrate), an oral, ferric iron-based compound that has the capacity to bind to phosphate in the gastrointestinal tract and form non-absorbable complexes. The company has completed Phase III clinical program for Zerenex for the treatment of hyperphosphatemia (elevated phosphate levels) in patients with chronic kidney disease on dialysis. Zerenex has also completed a Phase II study for the management of elevated serum phosphorus levels and iron deficiency anemia in patients with stages three to five non-dialysis dependent chronic kidney disease. The company has sublicense agreements with Japan Tobacco Inc. and Torii Pharmaceutical Co., Ltd. for the development and commercialization of Zerenex in Japan. It also has strategic alliances with Panion & BF Biotech, Inc. Keryx Biopharmaceuticals, Inc. was founded in 1997 and is headquartered in New York, New York.

88 Employees
Last Reported Date: 08/7/14
Founded in 1997

keryx biopharmaceuticals (KERX) Top Compensated Officers

Chief Executive Officer, Director and Member ...
Total Annual Compensation: $475.0K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $405.0K
Compensation as of Fiscal Year 2013.

keryx biopharmaceuticals (KERX) Key Developments

Keryx Biopharmaceuticals Inc. - Special Call

To discuss the approval of Ferric Citrate

Keryx Biopharmaceuticals, Inc. Receives FDA Approval of Ferric Citrate

Keryx Biopharmaceuticals Inc. announced that the U.S. Food and Drug Administration approved Ferric Citrate for the control of serum phosphorus levels in patients with chronic kidney disease on dialysis. The U.S. approval of Ferric Citrate was based on data from its Phase 3 registration program. In the Phase 3 clinical trials, Ferric Citrate effectively reduced serum phosphorus levels to well within the KDOQI guidelines range of 3.5 mg/dL to 5.5 mg/dL. In addition to the effects on serum phosphorus levels, Ferric Citrate's pharmacodynamic properties resulted in increased ferritin and transferrin saturation; whereas these parameters remained relatively constant in patients treated with active control. The most common adverse events for Ferric Citrate treated patients were gastrointestinal-related, including diarrhea, nausea, vomiting and constipation. Recently, the company was informed by the FDA that approval of the brand name Zerenex had been rescinded. Keryx believes the company will have an approved brand name on or prior to launch, although a brand name is not a pre-requisite for the launch of an FDA-approved drug.

Keryx Biopharmaceuticals Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014

Keryx Biopharmaceuticals Inc. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2014. For the quarter, the company’s net loss was $22.4 million, or $0.24 per share, compared to a net loss of $11.4 million, or $0.14 per share, for the comparable quarter in 2013, representing an increase in net loss of $11.0 million. The net loss for the second quarter ended June 30, 2014, included $2.6 million of non-cash compensation expense related to equity incentive grants. Operating loss was $22,543,000 compared to $11,454,000 a year ago. For the six months, the company’s net loss was $35.9 million, or $0.40 per share, compared to a net loss of $13.4 million, or $0.17 per share, for the comparable period in 2013, representing an increase in net loss of $22.5 million. The net loss for the six months ended June 30, 2014, included $5.2 million of non-cash compensation expense related to equity incentive grants. License revenue was $10,000,000 compared to $7,000,000 a year ago. Operating loss was $36,194,000 compared to $13,612,000 a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
KERX:US $13.48 USD -0.20

KERX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for KERX.
View Industry Companies
 

Industry Analysis

KERX

Industry Average

Valuation KERX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 123.4x
Price/Book 9.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 110.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact KERYX BIOPHARMACEUTICALS, please visit www.keryx.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.